Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Buy
64
CADL Quote, Financials, Valuation and Earnings
Last price:
$6.74
Seasonality move
:
-18.58%
Day range:
$6.81 - $7.25
52-week range:
$3.79 - $14.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,124.14x
P/B ratio:
4.64x
Volume:
1.3M
Avg. volume:
1M
1-year change:
5.33%
Market cap:
$346.7M
Revenue:
--
EPS (TTM):
-$1.34
Analysts' Opinion
-
Consensus RatingCandel Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.00, Candel Therapeutics has an estimated upside of 203.47% from its current price of $6.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $6.92.
Fair Value
-
According to the consensus of 5 analysts, Candel Therapeutics has 203.47% upside to fair value with a price target of $21.00 per share.
CADL vs. S&P 500
-
Over the past 5 trading days, Candel Therapeutics has overperformed the S&P 500 by 11.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Candel Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Candel Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Candel Therapeutics reported revenues of --.
Earnings Growth
-
Candel Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Candel Therapeutics reported earnings per share of $0.13.
Enterprise value:
264.6M
EV / Invested capital:
--
Price / LTM sales:
2,124.14x
EV / EBIT:
--
EV / Revenue:
2,134.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.72x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$35.3M | -$36.7M | -$33.6M | -$7.9M | -$8.1M | |
| EBITDA | -$23.7M | -$33.8M | -$36.8M | -$7.3M | $7.9M | |
| Diluted EPS | -$0.92 | -$1.28 | -$1.34 | -$0.28 | $0.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29.5M | $95.6M | $61.9M | $27.1M | $93.1M | |
| Total Assets | $35.1M | $101.6M | $67.2M | $31.2M | $95.9M | |
| Current Liabilities | $5.5M | $5.5M | $5.2M | $13.5M | $20.1M | |
| Total Liabilities | $62.6M | $37.8M | $27.6M | $25.2M | $21.2M | |
| Total Equity | -$27.5M | $63.8M | $39.7M | $6M | $74.7M | |
| Total Debt | $966K | $20.5M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34.2M | -$31.9M | -$27.2M | -$8.4M | -$8.6M | |
| Cash From Investing | -$1.1M | -$306K | -$12K | -$7K | -$3K | |
| Cash From Financing | $58K | -$1.4M | $93.7M | -$1.3M | -$1.9M | |
| Free Cash Flow | -$35.4M | -$32.2M | -$27.2M | -$8.4M | -$8.6M | |
CADL
Sector
Market Cap
$346.7M
$35.2M
Price % of 52-Week High
47.4%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
5.33%
-36.85%
Beta (5-Year)
--
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.22
200-day SMA
Buy
Level
$6.36
Bollinger Bands (100)
Buy
Level
4.57 - 7.45
Chaikin Money Flow
Sell
Level
-55.4M
20-day SMA
Buy
Level
$5.44
Relative Strength Index (RSI14)
Buy
Level
69.53
ADX Line
Buy
Level
27.85
Williams %R
Sell
Level
-13.0911
50-day SMA
Buy
Level
$5.41
MACD (12, 26)
Buy
Level
0.35
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
426M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Stock Forecast FAQ
In the current month, CADL has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CADL average analyst price target in the past 3 months is $21.00.
-
Where Will Candel Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Candel Therapeutics share price will rise to $21.00 per share over the next 12 months.
-
What Do Analysts Say About Candel Therapeutics?
Analysts are divided on their view about Candel Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Candel Therapeutics is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Candel Therapeutics's Price Target?
The price target for Candel Therapeutics over the next 1-year time period is forecast to be $21.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CADL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Candel Therapeutics is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CADL?
You can purchase shares of Candel Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Candel Therapeutics shares.
-
What Is The Candel Therapeutics Share Price Today?
Candel Therapeutics was last trading at $6.74 per share. This represents the most recent stock quote for Candel Therapeutics. Yesterday, Candel Therapeutics closed at $6.92 per share.
-
How To Buy Candel Therapeutics Stock Online?
In order to purchase Candel Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
80
SOC alert for Jul 18
Sable Offshore [SOC] is up 11.86% over the past day.
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 5.56% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.31% over the past day.
